Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats moderate to severe plaque psoriasis (PsO). Sold as Cosentyx. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Secukinumab (sold as Cosentyx), first approved Jan 21, 2015, with 15 new uses approved and 0 published complete response letters.
First approved: Jan 21, 2015
Applications: 2
New uses approved: 15
Complete response letters: 0
Medicare spending, 2025: $2.44B
First approved in the EU: Jan 14, 2015
First approved in Japan: Dec 26, 2014
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 1 month before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
CosentyxDrugs with a new additional pediatric dosage and a drug in an additional dosage form indicated for the treatment of plaque psoriasis, psoriatic arthritis,… · Novartis Pharma K.K. · Sep 27, 2021
CosentyxDrugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently… · Novartis Pharma K.K. · Aug 21, 2020
CosentyxDrugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to… · Novartis Pharma K.K. · Dec 21, 2018
CosentyxDrugs with a new additional indication for the treatment of pustular psoriasis in patients who have not responded sufficiently to conventional therapies. · Novartis Pharma K.K. · Dec 21, 2015 · Review report
Cosentyx, new ingredientDrugs with a new active ingredient indicated for the treatment of plaque psoriasis and psoriatic arthritis in patients who have not responded sufficiently… · Novartis Pharma K.K. · Dec 26, 2014 · Review report
Clinical Trials
50 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
